Allele Biotechnology and Pharmaceuticals, Inc. v. Regeneron Pharmaceuticals, Inc.

  1. October 04, 2024

    Regeneron Can't Ax Willful Infringement In COVID Patent Case

    Regeneron Pharmaceuticals Inc. cannot boot a willful infringement claim from Allele Biotech's patent suit over the development of COVID-19 vaccines and treatments, a New York federal judge ruled Friday, saying it was up to Regeneron to establish that Allele failed to show the defendant had presuit knowledge of the patent.

  2. September 19, 2023

    Regeneron Partly Agrees It Infringed COVID Tech Patent

    Regeneron Pharmaceuticals Inc. has agreed in part that it infringed a California company's patent when developing and testing COVID-19 vaccines and treatments, although it maintained that any liability it may have would not extend to activities covered by a federal safe harbor.

  3. March 02, 2022

    ​​​​​​​Regeneron Can't Ditch COVID-19 Tech Patent Suit

    Regeneron Pharmaceuticals Inc. can't escape a suit claiming it used poached technology in its development and testing of COVID-19 vaccines and treatments, a New York federal judge ruled Wednesday.

  4. August 20, 2021

    Regeneron Wants COVID-19 Tech Patent Suit Axed

    Regeneron Pharmaceuticals Inc. wants a New York federal judge to toss a suit claiming it used poached technology in its development and testing of COVID-19 vaccines and treatments, saying the company is protected by a legal safe harbor.

  5. October 09, 2020

    COVID-19 IP Catch-Up: Moderna Promises & Ed Sheeran

    In this round of intellectual property updates tied to the COVID-19 pandemic, Moderna said it would hold off on enforcing certain patents and Ed Sheeran said getting to the U.S. for a copyright trial may be impossible, among many other litigation updates. 

  6. October 05, 2020

    Pfizer, Regeneron Hit With Patent Suits Over COVID-19 Tech

    Pfizer Inc. and Regeneron Pharmaceuticals Inc. were accused Monday of using poached technology in their development and testing of COVID-19 vaccines and treatments, according to a pair of patent infringement suits lodged in California and New York federal court.